clinical trial · NCT06850480
A Phase III Clinical Trial for Efficacy and Safety Evaluation of JP-1366 Tablets on Reflux Esophagitis
Reflux Esophagitis (RE)JP-1366 simulation tabletsEsomeprazole Magnesium (Nexium) simulation tablets
brief summary
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
started
Dec 5, 2024
primary completion
Apr 15, 2025
completion
Apr 30, 2025
last updated
Feb 27, 2025
detailed description
To evaluate the efficacy and safety of JP-1366 tablets and Nexium® (Esomeprazole magnesium enteric-coated tablets) in subjects with reflux esophagitis.
official title
A Multicenter, Randomized, Double-blind, Double-simulated, Positive Parallel-control Phase III Clinical Trails of JP-1366（Zastaprazan Citrate） Tablets and Nexium® on Reflux Esophagitis
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol